VAC Coverage for Psychedelic-Assisted Therapy

For Canadian veterans with service-connected conditions, Veterans Affairs Canada (VAC) is the primary coverage pathway for psychedelic-assisted therapy — but coverage varies substantially by substance. Ketamine has the most established VAC coverage: VAC covers ketamine drug forms (IV, oral, intranasal Spravato, compounded cream) for service-related TRD (treatment-resistant depression) and chronic pain on a case-by-case basis. Per the December 2024 VAC mental-health treatments briefing, approximately 433 veterans averaged ~$10,109 in FY2024-25 ketamine coverage — established infrastructure with documented case volume. MDMA-AT is considered case-by-case for service-related PTSD where SAP-approved — less streamlined than ketamine but a real pathway, particularly relevant given Mithoefer 2018 Lancet Psychiatry Phase 2 evidence specifically in service-connected populations. VAC does NOT currently cover psilocybin-assisted therapy, citing insufficient evidence in veteran-specific populations — a meaningful contrast to ketamine and MDMA. This article walks through the cross-substance VAC pathway honestly.

Key takeaways

• Ketamine — established VAC coverage: ~433 veterans averaged ~$10,109 in FY2024-25 per VAC mental-health treatments briefing. Drug forms (IV, oral, Spravato, compounded cream) covered for service-related TRD/chronic pain on case-by-case basis.
• MDMA-AT — case-by-case for service-related PTSD: where SAP-approved. Less streamlined than ketamine; real pathway given Mithoefer 2018 evidence in service-connected populations.
• Psilocybin — NOT VAC-covered: VAC does not currently cover psilocybin-assisted therapy. Meaningful contrast to ketamine and MDMA.
• Eligibility framework: Canadian Armed Forces, RCMP, eligible service-connected conditions. PTSD, TRD, chronic pain — most common.
• Application sequence: identify SAP-trained or off-label-pathway clinician → document conventional treatment failures → for SAP substances, Health Canada SAP authorization → VAC mental-health benefits application → VAC review → if approved, treatment with reimbursement.
• Why ketamine is most accessible: established formal coverage pathway; broad Canadian off-label legal availability; multiple delivery options (IV, IM, sublingual, Spravato).
• ATMA CENA's role: supports preparation and integration via coordinated care in coordination with VAC mental-health teams and prescribing physicians.

Who is VAC-eligible?

Veterans Affairs Canada provides health benefits to:

• Canadian Armed Forces (CAF) veterans with eligible service
• Canadian Armed Forces members on retirement (active CAF members covered through Canadian Forces Health Services)
• Royal Canadian Mounted Police (RCMP) with eligible service
• Dependants and survivors of eligible service members

For coverage details, see Veterans Affairs Canada — Mental Health Benefits.

The service-related qualification is critical. VAC covers conditions connected to service in the Canadian Armed Forces, RCMP, or other eligible service. Civilian conditions without service connection are not VAC-eligible (these patients pursue private insurance, provincial drug plans, or other pathways).

Ketamine — established VAC coverage

VAC has the most developed coverage pathway for ketamine. The reasons:

1. Health Canada anaesthetic approval for ketamine and TRD approval for Spravato create regulatory clarity
2. Multiple delivery options (IV, IM, sublingual, intranasal Spravato, compounded cream) — VAC can match coverage to clinical need
3. Substantial published evidence in service-connected populations including veterans
4. Operational case volume has built infrastructure: approximately 433 veterans averaged ~$10,109 in FY2024-25, per the December 2024 VAC mental-health treatments briefing

What VAC covers for ketamine

VAC covers ketamine drug forms case-by-case for:

• Treatment-resistant depression (TRD) — service-related, with documented failure of antidepressant trials
• Chronic pain including CRPS, refractory neuropathic pain, and serious-injury pain — service-related
• PTSD (alone or comorbid with TRD/chronic pain) — service-related

Specific ketamine forms VAC has covered:

• IV racemic ketamine (off-label psychiatric)
• Oral ketamine (off-label or compounded)
• Intranasal Spravato (Health Canada-approved esketamine for TRD)
• Compounded ketamine cream for refractory neuropathic pain

Practical VAC application sequence for ketamine

1. Identify a prescribing physician willing to prescribe ketamine for the service-related condition
2. Document conventional treatment failures (e.g., for TRD: ≥2 antidepressant trials at therapeutic dose for ≥6 weeks; for chronic pain: prior pain-medicine standard of care)
3. Submit VAC mental-health benefits application with treatment plan
4. VAC review — typically several weeks
5. If approved: treatment delivered with VAC reimbursement

For more detail on ketamine therapy: Ketamine Therapy for PTSD, Ketamine Therapy for Treatment-Resistant Depression, Ketamine Therapy for Chronic Pain.

MDMA-AT — case-by-case for service-related PTSD

VAC considers MDMA-AT case-by-case for service-related PTSD where SAP-approved. The pathway is documented but less streamlined than ketamine. Considerations:

• Strongest evidence base in psychedelic medicine: Mitchell 2021 MAPP1 (d≈0.91) and Mitchell 2023 MAPP2 (d≈1.0) Phase 3 trials
• Mithoefer 2018 Lancet Psychiatry specifically demonstrated efficacy in service-connected populations (military veterans, firefighters, police)
• SAP authorization required first — VAC review follows SAP approval
• Higher cost than ketamine (~CAD $7,500–$15,000 per program) — VAC reimbursement covers eligible portions case-by-case

Application sequence for MDMA-AT (more complex than ketamine)

1. Identify SAP-trained prescribing physician with PTSD/SAP experience
2. Document conventional PTSD treatment failures (TF-CBT, prolonged exposure, EMDR, SSRIs/SNRIs)
3. SAP application to Health Canada by prescribing physician (review 2–8 weeks in 2026)
4. If SAP-approved: VAC mental-health benefits application with treatment plan
5. VAC review — case-by-case
6. If VAC-approved: deliver three-session MDMA-AT program

Total timeline from initial inquiry to dosing-day phase: typically 3–6 months.

For more detail on MDMA-AT: MDMA-Assisted Therapy for Veterans, MDMA-Assisted Therapy for PTSD.

Psilocybin — does NOT cover

VAC does not currently cover psilocybin-assisted therapy. This is a meaningful contrast to ketamine and MDMA. The reasons cited include insufficient evidence in veteran-specific populations.

For Canadian veterans pursuing psilocybin SAP for end-of-life distress, TRD, or other indications, the realistic pathway is out-of-pocket unless other coverage applies (Quebec RAMQ for end-of-life Quebec patients only). Given Filament Health's no-charge SAP psilocybin supply for many SAP-approved patients, drug cost is often $0; therapy fees ($2,500–$6,500 typical program) are out-of-pocket.

For Canadian veterans with comorbid TRD and PTSD where psilocybin-AT might apply for the depression/end-of-life component, the practical alternative is to pursue VAC coverage for the ketamine pathway (which is established for TRD) or the MDMA-AT pathway (case-by-case for PTSD).

For more detail on psilocybin therapy: Psilocybin Therapy in Canada, Psilocybin Therapy for Treatment-Resistant Depression.

How to think about the cross-substance VAC decision

A practical decision framework for veterans with service-connected conditions:

For service-related TRD:

• Ketamine pathway is most accessible. VAC has established ~433 veterans/year coverage for ketamine across delivery forms. Faster access timeline than MDMA-AT or psilocybin.
• Spravato specifically for TRD with concurrent oral SSRI/SNRI is the most-likely-covered ketamine form via VAC, given its Health Canada-approved indication.
• For ultra-resistant TRD, the Edmonton Misericordia/Grey Nuns IV ketamine program (AHCIP-covered for Alberta residents) provides an alternative public pathway.

For service-related PTSD:

• Ketamine pathway has established VAC infrastructure with smaller PTSD-specific effect sizes than MDMA-AT but broader access.
• MDMA-AT pathway has stronger PTSD-specific evidence (Mitchell 2021/2023 d≈0.91-1.0 vs ketamine pooled g≈0.20) but case-by-case VAC review is less streamlined.
• Many veterans pursue both at different times: ketamine for acute crisis stabilization or comorbid TRD; MDMA-AT later for trauma processing in a more stable phase.

For service-related chronic pain:

• Ketamine pathway has the strongest evidence base (CRPS specifically). VAC coverage established.
• Psilocybin and MDMA do not have chronic pain evidence; not VAC-covered for pain.

For the veterans-specific MDMA pathway: MDMA-Assisted Therapy for Veterans. For the cross-substance PTSD comparison: MDMA vs Ketamine for PTSD.

How ATMA CENA supports VAC-eligible veterans

ATMA CENA's role for Canadian veterans pursuing psychedelic-assisted therapy:

• The medical SAP application (for psilocybin or MDMA-AT) and the prescribing physician role (for ketamine) is initiated by the veteran's prescribing physician — typically a VAC-affiliated psychiatrist, a SAP-trained civilian psychiatrist, or other specialist.
• ATMA CENA supports preparation and integration through the three-phase psychedelic-assisted therapy model. For service-connected populations, this includes coordinated planning with VAC mental-health teams and family/spouse involvement where appropriate.
• The coordinated care model is particularly valuable for veterans with established trauma-focused therapist relationships. The existing therapist (often a VAC-affiliated trauma specialist) can remain primary while ATMA CENA's clinical infrastructure provides the dosing-specific frame.
• ATMA CENA's intake call screens for VAC eligibility and walks through which pathway (ketamine, MDMA-AT, etc.) is realistic given the veteran's service-connected diagnosis, prior treatment history, and access timeline.

Frequently asked questions

Does VAC cover psychedelic-assisted therapy? For ketamine: yes, established pathway for service-related TRD/chronic pain. For MDMA-AT: case-by-case for service-related PTSD where SAP-approved. For psilocybin: no — VAC does not currently cover.

How many veterans use VAC ketamine coverage? Per the December 2024 VAC mental-health treatments briefing, approximately 433 veterans averaged ~$10,109 in FY2024-25 ketamine coverage.

Why doesn't VAC cover psilocybin? VAC has cited insufficient evidence in veteran-specific populations. While the published psilocybin evidence base (Griffiths 2016, Ross 2016, Goodwin 2022) is strong for end-of-life distress and TRD generally, the veteran-specific evidence is more limited compared to ketamine and MDMA-AT.

What's the strongest evidence for VAC-covered psychedelic therapy? For ketamine: extensive RCT base in TRD (Berman 2000 onward; ELEKT-D 2023 NEJM non-inferior to ECT) and PTSD (Feder 2014, 2021). For MDMA-AT: Mithoefer 2018 Lancet Psychiatry specifically in military veterans, firefighters, police; Mitchell 2021/2023 Phase 3 confirmation.

What's the application sequence for VAC ketamine? Identify prescribing physician → document conventional treatment failures → submit VAC mental-health benefits application → VAC review → if approved, treatment with reimbursement.

What's the application sequence for VAC MDMA-AT? More complex than ketamine: identify SAP-trained prescriber → document failures → SAP application → if SAP-approved, VAC application → VAC review → treatment. Total 3–6 months typical.

Does VAC require service-connection? Yes. VAC covers conditions connected to service in CAF, RCMP, or other eligible service. Non-service-connected conditions are not VAC-eligible.

Are RCMP members eligible? Yes. RCMP veterans with eligible service are covered under VAC mental-health benefits.

What about active CAF members? Active CAF members are covered through Canadian Forces Health Services (not VAC). Coverage frameworks for psychedelic-assisted therapy in active CAF service vary; some service members may access through SAP and VAC after retirement transition.

What if my application is denied? VAC has appeal processes. Documentation of additional clinical justification, alternative treatment failures, or specialist consultation typically supports appeals. The ATMA CENA intake call can help orient you to alternatives if VAC denies coverage.

What about workers' compensation for veterans? Some veterans with post-service occupational exposure (e.g., wildland firefighting, corrections, paramedic work) may be eligible for provincial workers' compensation pathways in addition to or instead of VAC. See Workers' Compensation for Psychedelic-Assisted Therapy.

Is there a Canadian-veteran-specific clinic I should consider? Several Canadian providers have specific experience with veteran populations. The ATMA CENA intake call can orient you to providers with veteran-clinical-experience match. TheraPsil maintains a directory; MAPS Canada supports MDMA-AT advocacy.

Can family/spouse be involved in my treatment? For some MDMA-AT protocols (Monson 2020 ARROW), couples therapy structures can include spouses. Standard MDMA-AT and ketamine protocols typically focus on individual patient therapy. Coordination with family is part of the broader ATMA CENA intake call.

Sources

1. ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
2. Veterans Affairs Canada — Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
3. VAC Mental Health Treatments Briefing (December 2024): https://public.cdn.cloud.veterans.gc.ca/pdf/about-vac/who-we-are/department-officials/minister/briefing/dec2-2024/16-mental-health-treatments-en.pdf
4. Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
5. Mitchell JM, et al. (2021). MDMA-assisted therapy for severe PTSD: MAPP1 Phase 3. Nat Med. https://pubmed.ncbi.nlm.nih.gov/33972795/
6. Mitchell JM, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: MAPP2 Phase 3. Nat Med. https://pubmed.ncbi.nlm.nih.gov/37709999/
7. Mithoefer MC, et al. (2018). Phase 2 RCT in military veterans, firefighters, police. Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29728331/
8. TheraPsil: https://therapsil.ca/

Related articles

• Insurance Coverage for Psychedelic-Assisted Therapy in Canada
• PSHCP / Canada Life Spravato Coverage
• Alberta Blue Cross PAT Coverage
• Workers' Compensation for Psychedelic-Assisted Therapy
• MDMA-Assisted Therapy for Veterans
• Ketamine Therapy for PTSD
• MDMA vs Ketamine for PTSD
• Find care near you

Last updated: 2026-05-06